CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质瘤 CAR-T 细胞治疗的临床前模型
英文原题：Pre-Clinical Models for CAR T-Cell Therapy for Glioma.
查看英文原题
Pre-Clinical Models for CAR T-Cell Therapy for Glioma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗代表了癌症治疗的一种变革性转变。在众多基于免疫的方法中，嵌合抗原受体（CAR）T细胞疗法在治疗血液系统恶性肿瘤方面显示出有希望的结果。尽管有积极的治疗选择，恶性脑肿瘤患者的预后仍然很差。近年来，利用CAR-T 细胞疗法治疗脑肿瘤的研究激增。临床前模型对于在推进到临床试验之前评估这些疗法的安全性和有效性至关重要。然而，当前的模型在不同程度上重现了人类肿瘤环境。新的体外和体内技术为验证CAR-T 细胞疗法提供了机会，但也有局限性。通过评估各种临床前胶质瘤模型的优缺点，本综述旨在为脑肿瘤CAR-T 细胞疗法的开发和临床前测试提供路线图。
展开英文摘要原文
Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor. Research leveraging CAR T-cell therapy for brain tumors has surged in recent years. Pre-clinical models are crucial in evaluating the safety and efficacy of these therapies before they advance to clinical trials.
However, current models recapitulate the human tumor environment to varying degrees. Novel in vitro and in vivo techniques offer the opportunity to validate CAR T-cell therapies but also have limitations. By evaluating the strengths and weaknesses of various pre-clinical glioma models, this review aims to provide a roadmap for the development and pre-clinical testing of CAR T-cell therapies for brain tumors.
论文信息
- 作者
- Vandecandelaere G、Ramapriyan R、Gaffey M、Richardson LG、Steuart SJ、Tazhibi M、Kalaw A、Grewal EP
- 单位
- Brain Tumor Immunotherapy Lab, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cells2024 Sep 4
- 原文标识
- PubMed 39273050 · DOI 10.3390/cells13171480
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →